Eye treatment for ankylosing spondylitis

Treatment is selected after an eye examination confirms the type and location of inflammation. A painful red eye should not be managed with leftover drops or by waiting for a routine rheumatology visit.

Acute anterior uveitis, also called iritis, affects the front of the eye and is associated with ankylosing spondylitis. Prescription corticosteroid eye drops can suppress inflammation. Dilating drops may relax the focusing muscles, ease spasm-related pain, and help prevent the iris from sticking to nearby structures.

The precise medicines, dosing schedule, and taper depend on examination findings. More severe, persistent, or recurrent inflammation may require injections, tablets, or coordination with rheumatology about systemic immune-modifying treatment. These decisions require specialist supervision.

Use each drop exactly as prescribed and wash your hands before handling the bottle. Keep the nozzle away from the eye and lashes, and ask the pharmacist how to space different drops. Sunglasses may reduce light discomfort while inflammation settles.

Attend follow-up even if the eye feels better. The ophthalmologist may need to confirm that inflammation has cleared, measure eye pressure, and adjust the taper. Stopping steroid drops too quickly can allow inflammation to return, while prolonged unsupervised use can harm the eye.

Get urgent eye assessment for eye pain, pronounced redness, sensitivity to light, new floaters, flashing lights, or blurred vision. Seek emergency help for sudden loss of vision, a penetrating injury, or severe symptoms after a chemical exposure.

Contact the treating eye service if symptoms worsen after treatment begins, drops cause a concerning reaction, or the dosing plan is unclear. Tell both eye and rheumatology teams when uveitis recurs so they can consider the whole pattern of disease.

Ask how often to use each drop, whether any bottle needs shaking, how to taper safely, and which side effects require contact. Clarify when you will be rechecked and whether repeated eye inflammation warrants a discussion about systemic ankylosing spondylitis treatment.